MCID: EPN002
MIFTS: 62

Ependymoma

Categories: Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Ependymoma

MalaCards integrated aliases for Ependymoma:

Name: Ependymoma 54 60 30 56 6 17 74
Tanycytic Ependymoma 54 74
Papillary Ependymoma 54 74
Cellular Ependymoma 54 74
Classic Ependymoma 54 60
Who Grade Ii Ependymal Neoplasm 54
Epithelial Ependymoma 54
Clear Cell Ependymoma 54
Ependymoma, Familial 54

Characteristics:

Orphanet epidemiological data:

60
ependymoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: All ages;

Classifications:



Summaries for Ependymoma

NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 251636Disease definitionEpendymoma is the most frequent intramedullary tumor in adults (but accounts for only 10-12% of pediatric central nervous system tumors), and can be benign or anaplastic. Ependymoma arise from the ependymal cells of the cerebral ventricles, corticle rests and central canal of the spinal cord, and manifest with variable symptoms such headache, vomiting, seizures, focal neurological signs and loss of vision and can cause obstructive hydrocephalus in some cases.Visit the Orphanet disease page for more resources.

MalaCards based summary : Ependymoma, also known as tanycytic ependymoma, is related to malignant ependymoma and myxopapillary ependymoma. An important gene associated with Ependymoma is MEN1 (Menin 1), and among its related pathways/superpathways are DNA Damage and Neuroscience. The drugs Carboplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are ependymoma and migraine

Wikipedia : 77 An ependymoma is a tumor that arises from the ependyma, a tissue of the central nervous system. Usually,... more...

Related Diseases for Ependymoma

Diseases in the Ependymoma family:

Benign Ependymoma Malignant Ependymoma
Malignant Adult Ependymoma

Diseases related to Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 372)
# Related Disease Score Top Affiliating Genes
1 malignant ependymoma 34.0 GFAP NF2 RELA
2 myxopapillary ependymoma 33.9 GFAP MUC1 NCAM1 S100B VIM
3 cellular ependymoma 33.9 GFAP RELA SYP
4 anaplastic ependymoma 33.8 GFAP MUC1 NF2 RELA S100B SYP
5 brain ependymoma 33.7 EGFR MKI67
6 benign ependymoma 33.7 ENO2 GFAP NF2 SYP
7 tanycytic ependymoma 33.4 GFAP MEN1 NES NF2 SYP
8 clear cell ependymoma 33.2 ENO2 GFAP MUC1 SYP VIM
9 papillary ependymoma 32.3 ENO2 GFAP NES S100B SYP TTR
10 subependymal glioma 31.7 ENO2 GFAP SYP
11 subependymoma 31.6 ENO2 GFAP NCAM1 NES SYP
12 secretory meningioma 31.1 MUC1 VIM
13 angiocentric glioma 30.3 GFAP S100B SYP VIM
14 ependymoblastoma 30.3 GFAP NES VIM
15 chordoma 30.1 EGFR GFAP MUC1 S100B VIM
16 hemangioblastoma 30.1 ENO2 GFAP MUC1 S100B SYP
17 neurofibroma 30.0 MUC1 NF2 S100B SYP
18 medulloblastoma 30.0 EGFR ENO2 GFAP HOTAIR MGMT NCAM1
19 teratoma 29.9 ENO2 GFAP NES SYP
20 papilloma of choroid plexus 29.9 GFAP MUC1 S100B SYP TTR
21 tuberous sclerosis 29.9 GFAP S100B SYP VIM
22 chordoid meningioma 29.8 GFAP MUC1 S100B SYP VIM
23 medulloepithelioma 29.8 GFAP NES SYP VIM
24 embryonal sarcoma 29.8 MKI67 S100B VIM
25 meningioma, familial 29.7 ENO2 GFAP MEN1 MKI67 NF2 SYP
26 cystic teratoma 29.7 ENO2 GFAP SYP
27 renal cell carcinoma, nonpapillary 29.7 EGFR HOTAIR MUC1 VIM
28 malignant fibroxanthoma 29.7 MKI67 MUC1 S100B VIM
29 carcinoid syndrome 29.7 ENO2 MEN1 SYP
30 neuroma 29.7 ENO2 GFAP NF2 S100B
31 neurilemmoma 29.5 ENO2 GFAP NES NF2 S100B VIM
32 pheochromocytoma 29.5 ENO2 MEN1 NCAM1 SYP
33 ganglioneuroma 29.5 ENO2 GFAP NCAM1 SYP
34 ganglioglioma 29.5 ENO2 GFAP NES S100B SYP
35 oligodendroglioma 29.5 EGFR ENO2 GFAP MGMT S100B SYP
36 central neurocytoma 29.4 ENO2 GFAP NES SYP
37 hydrocephalus 29.4 ENO2 GFAP NES SYP TTR
38 neuroendocrine tumor 29.4 ENO2 MEN1 NCAM1 SYP
39 glioblastoma multiforme 29.4 EGFR GFAP MGMT NES RB1
40 astroblastoma 29.3 ENO2 GFAP NES SYP VIM
41 atypical teratoid rhabdoid tumor 29.2 GFAP HOTAIR SYP
42 gliosarcoma 28.8 EGFR ENO2 GFAP MGMT NES RB1
43 pediatric ependymoma 12.5
44 pediatric supratentorial ependymoma 12.3
45 adult brain ependymoma 12.3
46 spinal cord ependymoma 12.3
47 pediatric infratentorial ependymoma 12.2
48 rela fusion-positive ependymoma 12.2
49 brain stem ependymoma 12.0
50 malignant adult ependymoma 12.0

Graphical network of the top 20 diseases related to Ependymoma:



Diseases related to Ependymoma

Symptoms & Phenotypes for Ependymoma

Human phenotypes related to Ependymoma:

60 33 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ependymoma 60 33 obligate (100%) Obligate (100%) HP:0002888
2 migraine 60 33 frequent (33%) Frequent (79-30%) HP:0002076
3 pain 60 33 frequent (33%) Frequent (79-30%) HP:0012531
4 abnormal cell morphology 60 33 frequent (33%) Frequent (79-30%) HP:0025461
5 seizures 60 33 occasional (7.5%) Occasional (29-5%) HP:0001250
6 gait disturbance 60 33 occasional (7.5%) Occasional (29-5%) HP:0001288
7 vomiting 60 33 occasional (7.5%) Occasional (29-5%) HP:0002013
8 spinal cord tumor 60 33 occasional (7.5%) Occasional (29-5%) HP:0010302
9 distal muscle weakness 60 33 occasional (7.5%) Occasional (29-5%) HP:0002460
10 dysesthesia 60 33 occasional (7.5%) Occasional (29-5%) HP:0012534
11 supratentorial neoplasm 60 33 occasional (7.5%) Occasional (29-5%) HP:0030693
12 ovarian neoplasm 60 33 very rare (1%) Very rare (<4-1%) HP:0100615
13 neoplasm of the lung 60 33 very rare (1%) Very rare (<4-1%) HP:0100526
14 neoplasm of the breast 60 33 very rare (1%) Very rare (<4-1%) HP:0100013
15 neoplasm of the liver 60 33 very rare (1%) Very rare (<4-1%) HP:0002896

GenomeRNAi Phenotypes related to Ependymoma according to GeneCards Suite gene sharing:

27 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.91 RB1 TP73
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.91 MEN1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.91 TP73
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.91 EGFR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.91 EGFR RB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.91 MEN1 TIMP3 TP73
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.91 MEN1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.91 RB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.91 TIMP3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.91 TIMP3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.91 RB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.91 MEN1 RB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.91 EGFR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.91 TP73
15 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.91 TP73
16 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.91 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.91 RB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.91 EGFR
19 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.91 TIMP3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.91 EGFR MEN1 RB1 TIMP3 TP73
21 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.91 MEN1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.91 MEN1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.91 RB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.91 RB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.91 TIMP3
26 Increased shRNA abundance (Z-score > 2) GR00366-A-69 9.91 TP73
27 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.91 MEN1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.91 EGFR TIMP3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.91 TP73
30 Decreased cell migration GR00055-A-1 9.35 EGFR MUC1 NCAM1 NF2 VIM

MGI Mouse Phenotypes related to Ependymoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 EGFR GFAP MEN1 MGMT NF2 RB1
2 nervous system MP:0003631 9.9 EGFR ENO2 GFAP MEN1 NCAM1 NF2
3 digestive/alimentary MP:0005381 9.87 EGFR GFAP MEN1 RB1 RELA TP73
4 respiratory system MP:0005388 9.61 EGFR ENO2 MGMT NF2 RB1 RELA
5 vision/eye MP:0005391 9.32 EGFR GFAP NCAM1 NF2 RB1 RELA

Drugs & Therapeutics for Ependymoma

Drugs for Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
2
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
3
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
4
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
6
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
7
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
8
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
9
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
10
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
17
Valproic Acid Approved, Investigational Phase 2, Phase 3,Phase 1 99-66-1 3121
18
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6 774
19
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
20
Dopamine Approved Phase 3,Phase 2,Early Phase 1,Not Applicable 62-31-7, 51-61-6 681
21
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
23 Trofosfamide Investigational Phase 2, Phase 3 22089-22-1
24 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
25
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
26 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Folate Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
44 Keratolytic Agents Phase 3,Phase 2,Phase 1
45 Podophyllotoxin Phase 3,Phase 2,Phase 1 518-28-5
46 Narcotics Phase 3
47 Adjuvants, Anesthesia Phase 3
48 Analgesics Phase 3,Phase 2,Phase 1
49 Anesthetics, Intravenous Phase 3
50 Liver Extracts Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 265)
# Name Status NCT ID Phase Drugs
1 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
2 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
3 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Completed NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
7 An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
8 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine Sulfate Liposome
9 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
10 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
11 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
12 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Unknown status NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
13 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
14 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
15 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
16 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
17 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
18 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
19 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
20 Everolimus for Children With Recurrent or Progressive Ependymoma Completed NCT02155920 Phase 2 Everolimus
21 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
22 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
23 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
24 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
25 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
26 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
27 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
28 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
29 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
30 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
31 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
32 A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects Completed NCT00187226 Phase 2
33 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
34 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
35 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
36 Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors Completed NCT00006450 Phase 2 Phenylbutyrate
37 A Phase I/II Study of the Photon Radiosurgery System Completed NCT00179907 Phase 1, Phase 2
38 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
39 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
40 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2 Oxaliplatin
41 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
42 Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy Completed NCT00463203 Phase 2 Bevacizumab;Irinotecan
43 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
44 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
45 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
46 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
47 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
48 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
49 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
50 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy

Search NIH Clinical Center for Ependymoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Ependymoma

Genetic tests related to Ependymoma:

# Genetic test Affiliating Genes
1 Ependymoma 30

Anatomical Context for Ependymoma

MalaCards organs/tissues related to Ependymoma:

42
Brain, Spinal Cord, Bone, Lung, T Cells, Pituitary, Liver

Publications for Ependymoma

Articles related to Ependymoma:

(show top 50) (show all 1465)
# Title Authors Year
1
Microsurgical Resection of Anaplastic Ependymoma of the Cerebellopontine Angle in an Adult: 3-Dimensional Operative Video. ( 30295880 )
2019
2
Sudden Unexpected Death in a Child From an Anaplastic Ependymoma. ( 30958386 )
2019
3
Anaplastic ependymoma arising from the lower segment of the uterine corpus: Case report and literature review. ( 31060102 )
2019
4
A Case of Recurrent Supratentorial Extraventricular Anaplastic Ependymoma in Adult. ( 31062531 )
2019
5
Destructive arthropathy of the shoulder complicating a cervical ependymoma. ( 30890366 )
2019
6
A systematic review of outcome in intramedullary ependymoma and astrocytoma. ( 30833131 )
2019
7
Natural Course of Myxopapillary Ependymoma: Unusual Case Report and Review of Literature. ( 30321682 )
2019
8
Unusual features of ependymoma in a patient with Parkinson's disease. ( 30409527 )
2019
9
Long-Term Supratentorial Radiologic Effects of Surgery and Local Radiation in Children with Infratentorial Ependymoma. ( 30448581 )
2019
10
Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. ( 30452715 )
2019
11
Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial. ( 30460634 )
2019
12
Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma. ( 30483834 )
2019
13
Radiosurgery or hypofractionated stereotactic radiotherapy after craniospinal irradiation in children and adults with medulloblastoma and ependymoma. ( 30515559 )
2019
14
Surgical outcome in cortical ependymoma: A single centre experience of 18 cases. ( 30528353 )
2019
15
Individualized treatment for a case of recurrent ovarian ependymoma. ( 30588035 )
2019
16
Management of Ependymoma in Children, Adolescents and Young Adults. ( 30616927 )
2019
17
A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review. ( 30631904 )
2019
18
Clinical Characteristics and Prognostic Factors of Treatment in Pediatric Posterior Cranial Fossa Ependymoma. ( 30699434 )
2019
19
To Treat, or Not to Treat, That is the Question for a 13-Month-Old Girl with Cranial Ependymoma and an Unknown Spinal Mass. ( 30712706 )
2019
20
Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. ( 30768777 )
2019
21
Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. ( 30811284 )
2019
22
Re-irradiation of locally recurrent pediatric intracranial ependymoma: Experience of the French society of children's cancer. ( 30825956 )
2019
23
Myxopapillary Ependymoma. ( 30844350 )
2019
24
Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. ( 30850560 )
2019
25
The value of high-dose radiotherapy in intracranial ependymoma. ( 30865382 )
2019
26
Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues. ( 30868390 )
2019
27
Spinal melanotic ependymoma: A case report and review of literature. ( 30871914 )
2019
28
Ependymoma of the spinal cord in children. A Retrospective French study. ( 30877001 )
2019
29
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. ( 30883662 )
2019
30
Quantitative Analysis of Near-Infrared Indocyanine Green Videoangiography for Predicting Functional Outcomes After Spinal Intramedullary Ependymoma Resection. ( 30888018 )
2019
31
EZHIP / CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. ( 30923826 )
2019
32
Papillary Ependymoma of the Spinal Cord: A Case Report with Summary of Prior Published Cases. ( 30937039 )
2019
33
Cerebellopontine angle ependymoma in a young adult: A case report. ( 30946332 )
2019
34
Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial. ( 30976811 )
2019
35
Spinal Cord Ependymoma - Surgical Management and Outcome. ( 31001024 )
2019
36
Extramedullary Tanycytic Ependymoma in a 12-Year-Old Boy. ( 31001044 )
2019
37
High-dose chemotherapy with autologous stem cell transplantation in infants and young children with ependymoma: A 10-year experience with the Head Start II protocol. ( 31012212 )
2019
38
Resection of Myxopapillary Ependymoma of the Filum Terminale: 2-Dimensional Operative Video. ( 31073602 )
2019
39
PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. ( 31086175 )
2019
40
NF2 and ATRX gene copy number losses on a case of ovarian ependymoma. ( 29944970 )
2019
41
High Cervical Ependymoma Resection: 2-Dimensional Operative Video. ( 30107551 )
2019
42
Rapid autopsy of a patient with recurrent anaplastic ependymoma. ( 28942746 )
2018
43
RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging. ( 29063976 )
2018
44
Adult Supratentorial Extraventricular Anaplastic Ependymoma: Therapeutic Approach and Clinical Review. ( 29492136 )
2018
45
Pediatric Isolated Cortical (Ectopic) Anaplastic Ependymoma. ( 29492147 )
2018
46
Radiation necrosis following proton therapy successfully treated by low-dose bevacizumab in a patient with relapsed anaplastic ependymoma. ( 29667785 )
2018
47
Pineal Anaplastic Ependymoma With Multifocal Intradural Extramedullary Metastases on MRI and 18FDG-PET. ( 30080187 )
2018
48
Preoperative and intraoperative perfusion magnetic resonance imaging in a RELA fusion-positive anaplastic ependymoma: A case report. ( 30105138 )
2018
49
Pediatric Case of Li-Fraumeni Syndrome Complicated with Supratentorial Anaplastic Ependymoma. ( 30196175 )
2018
50
Intramedullary spinal cord ependymoma and astrocytoma: intraoperative frozen-section diagnosis, extent of resection, and outcomes. ( 30485241 )
2018

Variations for Ependymoma

ClinVar genetic disease variations for Ependymoma:

6 (show top 50) (show all 73)
# Gene Variation Type Significance SNP ID Assembly Location
1 MSH6 NM_000179.2(MSH6): c.866_867delGCinsAA (p.Gly289Glu) indel Uncertain significance rs267608079 GRCh37 Chromosome 2, 48025988: 48025989
2 MSH6 NM_000179.2(MSH6): c.866_867delGCinsAA (p.Gly289Glu) indel Uncertain significance rs267608079 GRCh38 Chromosome 2, 47798849: 47798850
3 RET NM_020975.4(RET): c.1699G> A (p.Asp567Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs147219360 GRCh37 Chromosome 10, 43608351: 43608351
4 RET NM_020975.4(RET): c.1699G> A (p.Asp567Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs147219360 GRCh38 Chromosome 10, 43112903: 43112903
5 MEN1 NM_000244.3(MEN1): c.711dup (p.Lys238Glnfs) duplication Pathogenic rs1555165565 GRCh37 Chromosome 11, 64575111: 64575111
6 MEN1 NM_000244.3(MEN1): c.711dup (p.Lys238Glnfs) duplication Pathogenic rs1555165565 GRCh38 Chromosome 11, 64807639: 64807639
7 GON4L NM_001282856.1(GON4L): c.2455A> G (p.Asn819Asp) single nucleotide variant Uncertain significance rs1553200563 GRCh37 Chromosome 1, 155742897: 155742897
8 GON4L NM_001282856.1(GON4L): c.2455A> G (p.Asn819Asp) single nucleotide variant Uncertain significance rs1553200563 GRCh38 Chromosome 1, 155773106: 155773106
9 HDAC3 NM_003883.3(HDAC3): c.50_55+5delACTACGGTGAG deletion Uncertain significance rs1554218152 GRCh37 Chromosome 5, 141016298: 141016308
10 HDAC3 NM_003883.3(HDAC3): c.50_55+5delACTACGGTGAG deletion Uncertain significance rs1554218152 GRCh38 Chromosome 5, 141636731: 141636741
11 SETD9 NM_001323022.1(SETD9): c.329_337delACATTGCCT (p.Ile111_Tyr113del) deletion Uncertain significance rs1554039146 GRCh37 Chromosome 5, 56210766: 56210774
12 SETD9 NM_001323022.1(SETD9): c.329_337delACATTGCCT (p.Ile111_Tyr113del) deletion Uncertain significance rs1554039146 GRCh38 Chromosome 5, 56914939: 56914947
13 BANP NM_079837.2(BANP): c.575A> G (p.Asn192Ser) single nucleotide variant Uncertain significance rs1555586650 GRCh37 Chromosome 16, 88052070: 88052070
14 BANP NM_079837.2(BANP): c.575A> G (p.Asn192Ser) single nucleotide variant Uncertain significance rs1555586650 GRCh38 Chromosome 16, 88018464: 88018464
15 SUV39H1 NM_003173.3(SUV39H1): c.415C> T (p.Arg139Cys) single nucleotide variant Uncertain significance rs368779259 GRCh37 Chromosome X, 48558731: 48558731
16 SUV39H1 NM_003173.3(SUV39H1): c.415C> T (p.Arg139Cys) single nucleotide variant Uncertain significance rs368779259 GRCh38 Chromosome X, 48700340: 48700340
17 TASOR NM_001112736.1(TASOR): c.97G> A (p.Glu33Lys) single nucleotide variant Uncertain significance rs1553733337 GRCh37 Chromosome 3, 56716938: 56716938
18 TASOR NM_001112736.1(TASOR): c.97G> A (p.Glu33Lys) single nucleotide variant Uncertain significance rs1553733337 GRCh38 Chromosome 3, 56682910: 56682910
19 POU3F4 NM_000307.4(POU3F4): c.1013C> T (p.Pro338Leu) single nucleotide variant Uncertain significance rs1555984638 GRCh37 Chromosome X, 82764345: 82764345
20 POU3F4 NM_000307.4(POU3F4): c.1013C> T (p.Pro338Leu) single nucleotide variant Uncertain significance rs1555984638 GRCh38 Chromosome X, 83509337: 83509337
21 PATZ1 NM_032050.1(PATZ1): c.562G> T (p.Asp188Tyr) single nucleotide variant Uncertain significance rs1555894069 GRCh37 Chromosome 22, 31741027: 31741027
22 PATZ1 NM_032050.1(PATZ1): c.562G> T (p.Asp188Tyr) single nucleotide variant Uncertain significance rs1555894069 GRCh38 Chromosome 22, 31345041: 31345041
23 KAT6B NM_012330.3(KAT6B): c.3827C> T (p.Pro1276Leu) single nucleotide variant Uncertain significance rs1554845417 GRCh37 Chromosome 10, 76788409: 76788409
24 KAT6B NM_012330.3(KAT6B): c.3827C> T (p.Pro1276Leu) single nucleotide variant Uncertain significance rs1554845417 GRCh38 Chromosome 10, 75028651: 75028651
25 KREMEN2 NM_172229.2(KREMEN2): c.494G> T (p.Gly165Val) single nucleotide variant Uncertain significance rs1210829529 GRCh37 Chromosome 16, 3016650: 3016650
26 KREMEN2 NM_172229.2(KREMEN2): c.494G> T (p.Gly165Val) single nucleotide variant Uncertain significance rs1210829529 GRCh38 Chromosome 16, 2966649: 2966649
27 DEPDC5 NM_001242897.1(DEPDC5): c.2705G> A (p.Trp902Ter) single nucleotide variant Uncertain significance rs1555900957 GRCh37 Chromosome 22, 32241141: 32241141
28 DEPDC5 NM_001242897.1(DEPDC5): c.2705G> A (p.Trp902Ter) single nucleotide variant Uncertain significance rs1555900957 GRCh38 Chromosome 22, 31845155: 31845155
29 NET1 NM_001047160.2(NET1): c.498G> T (p.Glu166Asp) single nucleotide variant Uncertain significance rs1554818513 GRCh37 Chromosome 10, 5494455: 5494455
30 NET1 NM_001047160.2(NET1): c.498G> T (p.Glu166Asp) single nucleotide variant Uncertain significance rs1554818513 GRCh38 Chromosome 10, 5452492: 5452492
31 SPRY3 NM_005840.2(SPRY3): c.55C> T (p.Arg19Cys) single nucleotide variant Uncertain significance rs779201129 GRCh37 Chromosome X, 155003588: 155003588
32 SPRY3 NM_005840.2(SPRY3): c.55C> T (p.Arg19Cys) single nucleotide variant Uncertain significance rs779201129 GRCh38 Chromosome X, 155773926: 155773926
33 SPRY3 NM_005840.2(SPRY3): c.55C> T (p.Arg19Cys) single nucleotide variant Uncertain significance rs779201129 GRCh38 Chromosome Y, 56960446: 56960446
34 VBP1 NM_003372.6(VBP1): c.331C> A (p.Leu111Met) single nucleotide variant Uncertain significance rs1000821034 GRCh37 Chromosome X, 154456711: 154456711
35 VBP1 NM_003372.6(VBP1): c.331C> A (p.Leu111Met) single nucleotide variant Uncertain significance rs1000821034 GRCh38 Chromosome X, 155228429: 155228429
36 ARHGAP32 NM_001142685.1(ARHGAP32): c.4703C> G (p.Thr1568Ser) single nucleotide variant Uncertain significance rs749174548 GRCh37 Chromosome 11, 128840363: 128840363
37 ARHGAP32 NM_001142685.1(ARHGAP32): c.4703C> G (p.Thr1568Ser) single nucleotide variant Uncertain significance rs749174548 GRCh38 Chromosome 11, 128970468: 128970468
38 OTUD5 NM_017602.3(OTUD5): c.1702C> A (p.Pro568Thr) single nucleotide variant Uncertain significance rs1295653938 GRCh37 Chromosome X, 48780465: 48780465
39 OTUD5 NM_017602.3(OTUD5): c.1702C> A (p.Pro568Thr) single nucleotide variant Uncertain significance rs1295653938 GRCh38 Chromosome X, 48923188: 48923188
40 KLHL21 NM_001324309.1(KLHL21): c.501G> C (p.Glu167Asp) single nucleotide variant Uncertain significance rs1292721663 GRCh37 Chromosome 1, 6662377: 6662377
41 KLHL21 NM_001324309.1(KLHL21): c.501G> C (p.Glu167Asp) single nucleotide variant Uncertain significance rs1292721663 GRCh38 Chromosome 1, 6602317: 6602317
42 NF2 NM_000268.3(NF2): c.551G> A (p.Trp184Ter) single nucleotide variant Likely pathogenic rs1555993293 GRCh37 Chromosome 22, 30051617: 30051617
43 NF2 NM_000268.3(NF2): c.551G> A (p.Trp184Ter) single nucleotide variant Likely pathogenic rs1555993293 GRCh38 Chromosome 22, 29655628: 29655628
44 LATS1 NM_001350339.1(LATS1): c.2050G> C (p.Asp684His) single nucleotide variant Uncertain significance rs750318192 GRCh37 Chromosome 6, 150001239: 150001239
45 LATS1 NM_001350339.1(LATS1): c.2050G> C (p.Asp684His) single nucleotide variant Uncertain significance rs750318192 GRCh38 Chromosome 6, 149680103: 149680103
46 MAP4K3 NM_003618.3(MAP4K3): c.899T> C (p.Phe300Ser) single nucleotide variant Uncertain significance rs1268580645 GRCh37 Chromosome 2, 39552678: 39552678
47 MAP4K3 NM_003618.3(MAP4K3): c.899T> C (p.Phe300Ser) single nucleotide variant Uncertain significance rs1268580645 GRCh38 Chromosome 2, 39325537: 39325537
48 TRAF3 NM_145725.2(TRAF3): c.53C> G (p.Pro18Arg) single nucleotide variant Uncertain significance rs145456077 GRCh37 Chromosome 14, 103336591: 103336591
49 TRAF3 NM_145725.2(TRAF3): c.53C> G (p.Pro18Arg) single nucleotide variant Uncertain significance rs145456077 GRCh38 Chromosome 14, 102870254: 102870254
50 LETM1 NM_012318.2(LETM1): c.286G> A (p.Val96Met) single nucleotide variant Uncertain significance rs753905629 GRCh37 Chromosome 4, 1843382: 1843382

Cosmic variations for Ependymoma:

9 (show all 14)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5977674 RANBP2 central nervous system,spinal cord,glioma,anaplastic c.5736T>G p.S1912R 2:108766275-108766275 0
2 COSM23159 MEN1 central nervous system,fourth ventricle,glioma,ependymoma Grade III-IV c.1413G>A p.W471* 11:64804754-64804754 0
3 COSM150426 KMT2C central nervous system,spinal cord,glioma,anaplastic c.2963G>T p.C988F 7:152229936-152229936 0
4 COSM1179671 KMT2C central nervous system,spinal cord,glioma,anaplastic c.925C>T p.P309S 7:152273792-152273792 0
5 COSM253767 KMT2C central nervous system,spinal cord,glioma,anaplastic c.2959T>C p.Y987H 7:152229940-152229940 0
6 COSM227271 HSP90AB1 central nervous system,spinal cord,glioma,anaplastic c.2156G>A p.R719H 6:44253579-44253579 0
7 COSM327928 H3F3A central nervous system,spinal cord,glioma,anaplastic c.83A>T p.K28M 1:226064434-226064434 0
8 COSM3164376 GATA4 central nervous system,spinal cord,glioma,anaplastic c.1273G>A p.D425N 8:11758419-11758419 0
9 COSM5977673 ALOX12B central nervous system,spinal cord,glioma,anaplastic c.53C>T p.T18I 17:8087390-8087390 0
10 COSM4593267 central nervous system,spinal cord,glioma,anaplastic c.32C>T p.A11V 18:55403683-55403683 0
11 COSM253768 central nervous system,spinal cord,glioma,anaplastic c.2959T>C p.Y987H 7:152229940-152229940 0
12 COSM1179670 central nervous system,spinal cord,glioma,anaplastic c.925C>T p.P309S 7:152273792-152273792 0
13 COSM5977672 central nervous system,spinal cord,glioma,anaplastic c.53C>T p.T18I 17:8087390-8087390 0
14 COSM150427 central nervous system,spinal cord,glioma,anaplastic c.2963G>T p.C988F 7:152229936-152229936 0

Copy number variations for Ependymoma from CNVD:

7 (show top 50) (show all 1024)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13823 1 1 7200000 Deletion Ependymoma
2 15495 1 116080654 116108285 Amplification NHLH2 Ependymoma
3 15648 1 117745152 117779348 Deletion MAN1A2 Ependymoma
4 19381 1 150034000 245120000 Amplification Ependymoma
5 19382 1 150034000 245120000 Amplification Ependymoma
6 26308 1 198898833 198920273 Amplification LGR6 Ependymoma
7 31595 1 2869431 2902617 Amplification TLR5 Ependymoma
8 31803 1 3118000 5001000 Deletion Ependymoma
9 38299 10 101279725 101300855 Deletion NKX2 Ependymoma
10 38453 10 102724768 102752246 Deletion LZTS2 Ependymoma
11 38454 10 102724768 102752246 Deletion MRPL43 Ependymoma
12 38455 10 102724768 102752246 Deletion PEO1 Ependymoma
13 38456 10 102724768 102752246 Deletion SEMA4G Ependymoma
14 38866 10 105634726 105742493 Deletion OBFC1 Ependymoma
15 38867 10 105634726 105742493 Deletion SLK Ependymoma
16 38979 10 106855945 106907237 Deletion SORCS3 Ependymoma
17 39169 10 11151805 11236375 Deletion CUGBP2 Ependymoma
18 40763 10 13344307 13497936 Deletion PHYH Ependymoma
19 40764 10 13344307 13497936 Deletion SEPHS1 Ependymoma
20 40806 10 133827559 133847021 Amplification C10orf39 Ependymoma
21 40809 10 133852261 133910912 Deletion DPYSL4 Ependymoma
22 40810 10 133852261 133910912 Deletion STK32C Ependymoma
23 40887 10 134410586 134892955 Deletion C10orf92 Ependymoma
24 40888 10 134410586 134892955 Deletion C10orf93 Ependymoma
25 40889 10 134410586 134892955 Deletion GPR123 Ependymoma
26 40890 10 134410586 134892955 Deletion INPP5A Ependymoma
27 40891 10 134410586 134892955 Deletion KNDC1 Ependymoma
28 40892 10 134410586 134892955 Deletion NKX6 Ependymoma
29 41033 10 135073302 135095235 Amplification ECHS1 Ependymoma
30 41034 10 135073302 135095235 Amplification PAOX Ependymoma
31 41074 10 135176625 135276748 Deletion CYP2E1 Ependymoma
32 41075 10 135176625 135276748 Deletion FLJ44653 Ependymoma
33 41076 10 135176625 135276748 Deletion SYCE1 Ependymoma
34 41910 10 25665327 25756077 Deletion GPR158 Ependymoma
35 42307 10 3169189 3180797 Deletion PITRM1 Ependymoma
36 44077 10 5175582 5187881 Deletion AKR1CL1 Ependymoma
37 44224 10 53651276 53712562 Deletion PRKG1 Ependymoma
38 44704 10 6170011 6268419 Deletion RBM17 Ependymoma
39 45199 10 68970214 69114993 Deletion CTNNA3 Ependymoma
40 45273 10 69645873 69701073 Deletion ATOH7 Ependymoma
41 45408 10 70846341 70896472 Deletion TSPAN15 Ependymoma
42 45468 10 71234506 71351772 Deletion COL13A1 Ependymoma
43 45538 10 71990162 72295747 Deletion ADAMTS14 Ependymoma
44 45539 10 71990162 72295747 Deletion C10orf27 Ependymoma
45 45540 10 71990162 72295747 Deletion KIAA1274 Ependymoma
46 45541 10 71990162 72295747 Deletion PRF1 Ependymoma
47 45542 10 71990162 72295747 Deletion SGPL1 Ependymoma
48 45578 10 72636128 72774965 Deletion SLC29A3 Ependymoma
49 45579 10 72636128 72774965 Deletion UNC5B Ependymoma
50 45628 10 73121579 73231404 Deletion C10orf54 Ependymoma

Expression for Ependymoma

Search GEO for disease gene expression data for Ependymoma.

Pathways for Ependymoma

GO Terms for Ependymoma

Biological processes related to Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.65 NCAM1 RB1 RELA TP73 VIM
2 Bergmann glial cell differentiation GO:0060020 9.16 GFAP VIM
3 response to cobalamin GO:0033590 8.96 EGFR RELA
4 intermediate filament-based process GO:0045103 8.62 GFAP VIM

Molecular functions related to Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.28 EGFR GFAP RB1 RELA S100B SYP

Sources for Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....